Methods of inhibiting metastases

• US 20050032785A1
• Filed: 06/21/2004
• Published: 02/10/2005
• Est. Priority Date: 10/01/2001
• Status: Active Grant

• Current Assignee: Geistlich Pharma AG
• Original Assignee: Rhode Island Hospital
• Inventors: Wands, Jack R., Carlson, Rolf I., Maggio, Paul
• Granted Patent: US 7,122,541 B2
• Time in Patent Office: Days
• US Class Current: 514/223.800
• CPC Class Codes: A61K 31/549 having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.

Claims

1. A method of inhibiting the development of metastases of a primary tumor to a tissue of a liver in an individual after excision of the primary tumor, comprising directly contacting said tissue with taurolidine.

2. The method of claim 1, wherein said primary tumor is not a liver tumor.

3. The method of claim 1, wherein said primary tumor is in an organ of the peritoneal cavity.

4. The method of claim 1, wherein said individual is identified as being at risk of developing a metastatic liver tumor.

5. The method of claim 1, wherein said individual is a mammal.

6. The method of claim 5, wherein said mammal is a human.

7. The method of claim 1, wherein said individual is identified as suffering from a colorectal tumor.

8. The method of claim 1, wherein said individual is identified as suffering from a tumor selected from the group consisting of a lung tumor, breast tumor, kidney tumor, colon tumor, esophageal tumor, testicular tumor, pancreatic tumor, melanoma, and choriocarcinoma.

9. The method of claim 1, wherein said taurolidine is administered to said liver is by perfusion in a direction of naturally-occurring blood flow.

10. The method of claim 1, wherein said liver is perfused with said taurolidine in situ.

11. The method of claim 1, wherein said taurolidine is administered to said liver by retrograde perfusion.

13. The method of claim 9, wherein said perfusion is carried out in conjunction with an abdominal surgery.

14. The method of claim 1, wherein said Taurolidine is administered by in-dwelling catheter.

15. The method of claim 1, wherein said Taurolidine is administered at a dose which increased caspase activity in a cell.

16. The method of claim 1, wherein said Taurolidine is administered intravenously.

17. The method of claim 11, wherein said perfusion is carried out in conjunction with an abdominal surgery.

12. (Cancelled)

18. A method of inhibiting adherence of a tumor cell in metastases of a primary tumor to a tissue of a liver, comprising directly contacting said tissue with taurolidine.

19. A method of decreasing serum concentration of a tumor-associated antigen, comprising directly contacting said tissue with taurolidine.

20. The method of claim 19, wherein said tumor-associated antigen is carcinoembryonic antigen (CEA).

21. The method of claim 19, wherein said tumor-associated antigen is prostate-specific antigen (PSA).

22. A method of inhibiting the development of multicentric hepatocellular carcinoma in a tissue of a liver of an individual, comprising directly contacting said tissue with taurolidine.

23. The method of claim 22, wherein said individual is a mammal.

24. The method of claim 23, wherein said mammal is a human.

25. The method of claim 22, wherein said taurolidine is administered to said liver by perfusion in a direction of naturally-occurring blood flow.

26. The method of claim 25, wherein said perfusion is carried out in conjunction with an abdominal surgery.

27. The method of claim 22, wherein said liver is perfused with said taurolidine in situ.

28. The method of claim 22, wherein said taurolidine is administered to said liver by retrograde perfusion.

29. The method of claim 28, wherein said perfusion is carried out in conjunction with an abdominal surgery.

30. The method of claim 22, wherein said taurolidine is administered by in-dwelling catheter.

31. The method of claim 22, wherein said taurolidine is administered at a dose which increased caspase activity in a cell.

32. The method of claim 22, wherein said taurolidine is administered intravenously.

33. A method of monitoring inhibition of the development of metastases of a primary tumor to a tissue of a liver in an individual, comprising directly contacting said tissue with taurolidine and monitoring the development of said metastases in said tissue.

34. The method of claim 33, wherein the development of said metastases is monitored using a process selected from the group consisting of CT scan, ultrasound and liver biopsy.